Sweaty's Drugs: Neonatal, HRT Flashcards

(45 cards)

1
Q

general signs of drug withdrawal in infant

A

onset: varies depending on amount of drug accumulated and rate of release from tissue
lasts: weeks to months
signs: autonomic hyperactivity, irritable, excessive crying, poor feeding, abnormal reflexes
Tx: may have to re-expose and taper down

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

signs of opiate withdrawal in infant

A

CNS hyperactivity: tremor/ seizure, irritable, increased wakefulness, crying, hyperactive reflexes, frequent yawn/sneeze
autonomic hyperactivity: sweat, nasal stuffiness, mottling, fever
GI tract: diarrhea, poor feeding
CAN mimic other diseases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Determinants for drugs to cross placenta

A
  1. lipid solubility
  2. ionization
  3. Mol. Wt less than 600
  4. duration/timing of drug MOST important
  5. maternal plasma protein drug binding
  6. placental development and blood flow
  7. energy dependent transporters (consider polymorphisms)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

effects of placental drug metabolism

A

can increase/decrease fetal exposure

can also get SOME metabolism in fetal liver (only some blood goes straight to liver and liver is immature)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

requirements for teratogen designation

A
  1. characteristic set of malformations
  2. exert effects at a particular stage of fetal development
  3. show dose dependent incidence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What 2 species are candidate drugs required to be tested in?
Whys 2?

A

one rodent: usually rats
one non-rodent: usually rabbit
better chance of identifying teratogens: may be oversensitive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Mechanisms that contribute to teratogenity

A
  1. folate antagonism
  2. neural crest disruption
  3. endocrine disruption
  4. oxidative stress
  5. vascular disruption
  6. specific receptor or enzyme mediated events
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

SSRI in pregnancy

A

depression and SSRI can have adverse effects on fetus and pregnancy
SSRI effect in fetus: pulmonary artery HTN, others

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q
Pregnancy Category
A
B
C
D
X
A

risk benefit relationship
A: studies in PREGNANT WOMEN have not demonstrated risk in pregnancy
B: ANIMAL studies have not demonstrated risk; no adequate human reproduction study
C: ANIMAL studies have shown adverse effect on fetus OR no animal/human reproduction studies
D: evidence of fetal risk, but potential benefits may be acceptable despite risk in some circumstances
X: human or animal studies demonstrate fetal abnormalities, risk clearly outweighs benefit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Differences in infant drug metabolism (compared to adult)

  1. metabolic capacity
  2. body composition: fat, TBW
  3. plasma binding capacity
  4. renal function
  5. GI absorption
  6. IM absorption
  7. liver and brain/body weight ratio
  8. enzymes
  9. BBB permeability
  10. general trends
A
  1. poor
  2. less fat, more total body water
  3. lower: increases free drug in highly bound drugs
  4. immature: can alter elimination
  5. slower
  6. faster
  7. larger liver and brain to body weight ratio
  8. immature
  9. BBB more permeable
  10. longer T1/2, change in pharmacokinetics as neonate ages (over days rather than weeks or months)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How are drugs adjusted for children?

A

based on weight although surface area would be more accurate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q
  1. What drugs will concentrate in breast milk?
  2. Drugs less likely to be transferred?
  3. Drugs/methods preferred when breastfeeding?
A
  1. concentrate: BASIC, LIPID soluble
  2. less transferred: high protein bound drugs
  3. short T1/2 drugs, dose after feeding, most cautious early-post partum
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Groups of drugs that are problematic in breast feeding

A
  1. CNS acting drugs: sedation, infant dependence
  2. thyroid suppressors
  3. chloramphenical: blood dyscrasia, bone marrow suppression
  4. antidepressants: not sure of effect but lots passes to baby
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

mechanisms of paternal teratogenicity

major drug classes?

A
  1. mutation in DNA or altered gene expression
  2. direct contact with fetus
    drug classes: antivirals, anticancer, traditional and mAb, retinoids
    unexpected: androgen receptor antagonist, DMARD, anti epileptic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

TOXNET

A

website to find drug toxicity in utero and through breast milk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

LACTMED

A

part of TOXNET for breast milk

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Which menopausal signs will improve over time without treatment?
Which will not improve without treatment?

A

vasomotor: improve without Tx (may take years)
vaginal dryness: does not improve without Tx
undetermined: sleep and mood problems

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

CEE (conjugated equine estrogens) alone for HRT: Risks vs. Benefits

A

more balanced than CEE plus MPA

decreased risk: breast CA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

CEE plus MPA (medroxyprogesterone acetate) for HRT: Risks vs. Benefits

A

increased risk: CHD, breast CA, stroke, PE, gallbladder disease, dementia, urinary incontinence
decreased risk: hip fracture, DM, vasomotor symptoms

20
Q

Although most risks of HRT dissipate after Tx is discontinued, what risk remains?

21
Q

When is HRT appropriate?

A

moderate to severe menopausal symptoms in EARLY menopause (not for chronic disease prevention)

22
Q

HRT: vaginal estrogen

A

genitourinary symptoms without vasomotor symptoms

23
Q

CI for estrogen

A
  1. undiagnosed abnormal genital bleeding
  2. breast CA, estrogen dependent CA
  3. DVT, PE, stroke, MI
  4. liver dysfunction
  5. allergic to preparation
  6. pregnancy
24
Q

Caution with estrogen

A
  1. dementia
  2. gallbladder disease
  3. hypertriglyceridemia
  4. prior cholestatic jaundice
  5. hypothyroid
  6. fluid retention plus cardiac or renal dysfunctionn
  7. hypocalcemia
  8. prior endometriosis
  9. hepatic hemangiomas
25
Who gets HRT according to 10 yr CHD risk? 1. less than 5 years since LMP 2. 6-10 yrs 3. greater than 10 yrs
1. low risk: oral; mod. risk: transdermal 2. very low: oral; low to mod.: transdermal 3. AVOID also AVOID in anyone that is high risk for developing CHD
26
non-pharm Tx of vasomotor symptoms in menopause
cognitive behavioral therapy | other with caution: weight loss, stress reduction, soy isoflavones, stellate ganglion block
27
paroxetine
non-hormonal: antidepressant | Tx: vasomotor Sx (only FDA approved non hormonal)
28
fluoxetine
non-hormonal: antidepressant | Tx: vasomotor Sx (off label)
29
escitalopram
non-hormonal: antidepressant | Tx: vasomotor Sx (off label)
30
venlafaxine
non-hormonal: antidepressant Tx: vasomotor Sx (off label) AE: also anorexia, dry mouth, vomiting
31
clonidine
non-hormonal MOA: lowers peripheral vascular reactivity, raises sweating threshold Tx: vasomotor Sx (off label) AE: dry mouth, insomnia, drowsy
32
gabapentin
non-hormonal MOA for VMS: unclear Tx: vasomotor Sx (off label) AE: dizzy, unsteady, drowsy
33
MOA and AE for antidepressants used for vasomotor Sx
MOA for VMS: unknown | AE: nausea, headache, insomnia, sex dysfunction
34
17 B estradiol
oral, transdermal, vaginal estrogen
35
ethinyl estradiol
oral estrogen
36
conjugated estrogen
oral estrogen
37
medroxyprogesterone acetate
oral progestogen
38
norethindrone acetate
oral, transdermal progestogen
39
drospirenone
oral progestogen
40
micronized progesterone
oral progestogen
41
levonorgestril
transdermal progestogen
42
What is the MOST effective therapy for both VMS and Urogenital atrophy in menopause?
estrogen +/- progestogen | AE: breast tenderness, uterine bleeding, N/V, headache, weight change, rash, pruritus, cholecystitis
43
Why is transdermal estrogen preferred?
avoid first pass metabolism that promotes prothrombotic hemostatic changes in factor IX, protein C resistance, tPA activator less weight gain oral increases: coagulation effects, CRP, fibrolytic markers, worse effect on triglycerides both benefit: lipid profile (oral more so)
44
bazedoxifene
estrogen and SERM combo agonist is some tissues, antagonist in others use: menopause (reduces endometrial over growth)
45
What happens when HRT is stopped?
bone reposition accelerates, vulvovaginal atrophy recurs | half have VMS return